Display options
Cite
Peterlana D, Puccetti A, Simeoni S, et al. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol. 2004;24(1):18-21doi: 10.1007/s10067-004-0959-7.
Peterlana, D., Puccetti, A., Simeoni, S., Tinazzi, E., Corrocher, R., & Lunardi, C. (2005). Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clinical rheumatology, 24(1), 18-21. https://doi.org/10.1007/s10067-004-0959-7
Peterlana, D, et al. "Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases." Clinical rheumatology vol. 24,1 (2005): 18-21. doi: https://doi.org/10.1007/s10067-004-0959-7
Peterlana D, Puccetti A, Simeoni S, Tinazzi E, Corrocher R, Lunardi C. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol. 2005 Feb;24(1):18-21. doi: 10.1007/s10067-004-0959-7. Epub 2004 Jul 14. PMID: 15674654.
Copy Download .nbib Format: NLM
Share it on

Clin Rheumatol. 2005 Feb;24(1):18-21. doi: 10.1007/s10067-004-0959-7. Epub 2004 Jul 14.

Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases.

Clinical rheumatology

D Peterlana, A Puccetti, S Simeoni, E Tinazzi, R Corrocher, C Lunardi

Affiliations

  1. Department of Clinical and Experimental Medicine, Section of Internal Medicine B, Policlinico GB Rossi, University of Verona, P. le La Scuro, 37134 Verona, Italy.

PMID: 15674654 DOI: 10.1007/s10067-004-0959-7

Abstract

Human intravenous immunoglobulins (hIVIgs) are used in two broad categories of diseases: immunodeficiency and autoimmunity. Among the immune-mediated diseases hIVIgs are of benefit in idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and dermatomyositis. Chronic idiopathic pericarditis (CIP) is a chronic disease of unknown origin characterized by recurrent episodes of pericardial inflammation. The cause of the recurrence is unknown, although in some cases it may be traced to a viral infection and to the presence of antimyocardial antibodies. Since a viral infection can induce an autoimmune process through a mechanism of molecular mimicry, and since the optimal therapy for prevention of the recurrences has not been established, we reasoned that treatment with hIVIgs could be beneficial in our patients unresponsive to previous immunosuppressive therapies. We describe four patients affected by CIP treated with monthly high-dose hIVIgs (0.4 g/kg daily for 5 consecutive days) for five times followed by administration every 2 months. Three of the four patients could permanently discontinue steroid therapy and are still in remission after years of follow-up. Our experience suggests that hIVIgs therapy may be a useful and safe treatment for CIP in steroid-dependent patients.

References

  1. Science. 2001 Jan 19;291(5503):484-6 - PubMed
  2. Herz. 2000 Dec;25(8):748-54 - PubMed
  3. Transfus Med. 2002 Apr;12(2):133-9 - PubMed
  4. Rheumatology (Oxford). 2002 Apr;41(4):367-74 - PubMed
  5. N Engl J Med. 2001 Sep 6;345(10):747-55 - PubMed
  6. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  7. Eur Heart J. 1994 Jan;15(1):120-4 - PubMed
  8. Pediatrics. 1952 Jun;9(6):722-8 - PubMed
  9. BioDrugs. 2002;16(1):47-55 - PubMed
  10. J Am Coll Cardiol. 2003 Aug 20;42(4):759-64 - PubMed
  11. J Allergy Clin Immunol. 1997 Aug;100(2):151-7 - PubMed
  12. Clin Pediatr (Phila). 1996 Jan;35(1):23-31 - PubMed
  13. Rev Med Interne. 2001 Dec;22(12):1204-12 - PubMed
  14. Nat Med. 2000 Oct;6(10):1183-6 - PubMed
  15. Cardiol Clin. 1990 Nov;8(4):621-6 - PubMed
  16. Clin Cardiol. 1998 Nov;21(11):813-6 - PubMed
  17. Trends Immunol. 2003 Jan;24(1):2-4 - PubMed
  18. J Clin Immunol. 1990 Mar;10(2):81-9 - PubMed
  19. Ital Heart J. 2003 Jan;4(1):64-8 - PubMed
  20. J Allergy Clin Immunol. 2001 Oct;108(4 Suppl):S139-46 - PubMed
  21. Jpn Circ J. 1998 Nov;62(11):871-2 - PubMed
  22. Circulation. 1998 Jun 2;97(21):2183-5 - PubMed

Substances

MeSH terms

Publication Types